The results indicate that by Augment has a comparable treatment outcome while producing less pain and potential morbidity than traditional autograft bone harvesting and transplantation.
Read BioMemetic’s release on its Augment Bone Graft.
BioMimetic Updates Clinical Trial of Augment Bone Graft
BioMimetic Therapeutics’ Phase III trial comparing its fully synthetic, off-the-shelf bone growth factor product, Augment Bone Graft, to autograft for use in hindfoot and ankle fusion surgery, has shown positive top-line results, according to a release from BioMimetic.
Next Up in Uncategorized
-
From findings on cervical disc replacement to total knee replacement, Becker’s reported on eight spine and orthopedic studies since March…
-
Researchers at UMass Chan Medical School in Worcester, Mass., have created an algorithm to predict total knee replacement outcomes in…
-
Orthopaedic Solutions Management has acquired Orlando Hand Surgical Associates, marking its eighth acquisition. OHSA was founded in 2000 and has…
Comments are closed.